Ananta Technologies is focused on advancing cell therapy manufacturing through its innovative CentriFLEX™ bioreactor solution. This technology addresses significant challenges in the production of CAR-T therapies, which are increasingly recognized for their potential in treating cancer. The CentriFLEX bioreactor utilizes a centrifugal fluidized expansion method that allows for continuous feeding of fresh media while effectively removing cellular waste, thereby preventing cell product loss. This system not only enhances cell density and growth rates but also reduces manufacturing time by 30% compared to existing technologies. Its compact design and self-contained features, including HEPA filters and UV-C sterilization, eliminate the need for expensive cleanroom environments, making it a more accessible and cost-effective solution for CAR-T therapy production.

The CentriFLEX bioreactor stands out by resolving key bottlenecks in continuous cell culture, which is critical for meeting the high demand for CAR-T cells—up to 250 million cells per infusion. By eliminating the reliance on membrane filters, which are prone to fouling, Ananta Technologies has created a more efficient manufacturing process that promises to transform the landscape of cell therapy. This innovative approach not only aims to improve patient outcomes but also seeks to make advanced cancer treatments more scalable and widely available, ultimately benefiting healthcare systems and economies globally.

United States

Ananta has developed a centrifugal fluidized expansion (CentriFLEX) perfusion bioreactor that balances centrifugal forces with a continuous feed of fresh media. The CentriFLEX resolves a key manufacturing bottleneck in continuous cell culture. This instrument supplies fresh media, removes inhibitory cell waste, and prevents the loss of cell products.

Ananta Technologies

Company Details